The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

By P. Toth. 2012

1,358 citations recorded by the source corpus.

Subfields: Economics and Econometrics, Surgery

View Paper: https://www.semanticscholar.org/paper/3abbdc495cefbe2ff891b55e6d41bbdec1a0fab0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Economics and Econometrics

1. Kamlesh Khunti
2. G. Bakris
3. I. Graham
4. Tami Sadusky
5. Sylvia E. Rosas
6. K. Tuttle
7. Connie M. Rhee
8. R. Bilous

In Surgery

1. Jan Boren
2. I. Graham
3. Marja-Riitta Taskinen
4. Kamlesh Khunti
5. G. Bakris
6. Marcello Tonelli
7. Tami Sadusky
8. Sylvia E. Rosas

Citations in the corpus

• Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022, positive): “These recommendations are based largely on results of the Study of Heart and Renal Protection (SHARP) trial of CKD (48).”
• National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. (2015, neutral): “Cholesterol absorption inhibitor The Study of Heart and Renal Protection evaluated simvastatin 20 mg and ezetimibe 10 mg vs placebo in 9270 patients (3470 women, 37%) with chronic kidney disease (3023 on dialysis and 6247 non-dialysis dependent).(385) Treatment with simvastatin and ezetimibe produce”
• A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association (2023, neutral): “150”
• KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. (2012, positive): “2012;60(5):850-886 to support treatment with a statin-ezitimibe combination in patients with CKD.(77) This treatment reduced risks of major atherosclerotic events, but not deaths or health outcomes related to kidney disease.”
• Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association (2023, neutral): “105,106 Stage 3 CKM: Subclinical CVD and Risk Equivalents in CKM The goal of management in stage 3 CKM is to intensify preventive interventions in those with subclinical CVD, very high-risk CKD, or high predicted CVD risk to prevent progression to clinical CVD and kidney failure.”
• Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel (2017, positive): “85 mmol/L (33 mg/dL) and reduced the incidence of major cardiovascular events by 17% relative to placebo.(39) In both trials, the magnitude of the observed proportional risk reduction was consistent with the clinical benefit that would be expected from similar absolute reductions in LDL-C during tre”